What tirzepatide injection is used for — and what it actually does

You've heard the name; here's what the injection is actually prescribed to do

Picture this: you've been managing your weight for years, trying approaches that work for a while and then don't. A clinician or a search result mentions tirzepatide, and suddenly you're knee-deep in a mix of trial data, Instagram posts and conflicting prices. Frustrating, to put it mildly.

So here is the plain version. Tirzepatide injection (sold in the UK as Mounjaro) is licensed for two distinct uses. The first is weight management in adults with a BMI of 30 or above, or a BMI of 27 or above if you have at least one weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. The second licensed use is glycaemic control in type 2 diabetes, where it helps the body manage blood-sugar levels alongside diet and activity.

The mechanism behind both uses is the same. Tirzepatide binds to receptors for two hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Activating both pathways simultaneously produces a stronger effect on appetite and satiety than GLP-1 medicines alone. Your stomach empties more slowly, fullness signals arrive sooner, and calorie intake tends to fall, not through willpower, but through physiology. The NHS tirzepatide medicines page describes the mechanism and what to expect when starting treatment.

It is worth being clear about what tirzepatide does not do on its own: it is not a substitute for eating well or moving more. Every licence, every trial, every prescriber's assessment ties the medicine to a reduced-calorie diet and increased activity. The injection shifts the biological conditions; the lifestyle piece still matters.

The evidence behind the weight-management use

The weight-management use is the one most people asking this question are interested in. The SURMOUNT-1 trial (a 72-week randomised controlled study involving 2,539 adults with obesity, published in the New England Journal of Medicine) found that participants taking tirzepatide at the highest dose lost an average of around 20–21% of their body weight. That is a meaningful reduction by any clinical measure, and it is why NICE recommended tirzepatide for NHS use in late 2024.

NICE's appraisal (TA1026) sets the NHS eligibility threshold at a BMI of 35 or above with at least one weight-related comorbidity, though private prescribing follows the medicine's licensed indications, which start at BMI 30. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Criteria alone don't determine suitability; a prescriber reviews the full picture, including your medical history and current medicines.

Private treatment for weight management sits alongside, not instead of, the NHS route. For people who don't yet meet the NHS criteria or who prefer not to wait, a regulated online pharmacy is the legal alternative, provided the prescription comes from a qualified prescriber after a proper assessment. If you're curious about how that process works, our treatment page sets it out clearly.

How the injection is used: frequency, sites and the starting dose

Tirzepatide is injected once a week. Each Mounjaro KwikPen contains four doses (one per week for a month) and is injected into the skin of the abdomen, thigh or upper arm. Rotating injection sites each week is standard practice to avoid irritation; where exactly to inject is worth reading about before you start.

Treatment begins at 2.5 mg. That dose exists primarily to let your digestive system adjust, the gastrointestinal side effects that tirzepatide can cause tend to be most pronounced in the first few weeks, and a low starting dose significantly reduces them. Your prescriber titrates the dose upward over time, typically in 4-week steps, towards the dose that works for you. Deciding when to increase and by how much is a clinical decision, not something to self-direct; that conversation belongs with your prescriber.

Storage matters too. Mounjaro pens are kept refrigerated between 2–8°C; the exact window for keeping a pen at room temperature before use is set out in the Patient Information Leaflet, and the full injection guide covers preparation, technique and what to do if you miss a dose. You'll need to change the needle on each pen before injecting, and if you want guidance on choosing the right option, our page on needles for tirzepatide injection explains what to look for; using a fresh needle every time is both safer and more comfortable.

Side effects and who should be cautious

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping are all described in the trial data and the SmPC. They tend to cluster around dose increases and often ease after a week or two as your body adjusts. Fatigue, headaches and injection-site reactions also appear in the reported data.

Less common but more serious: acute pancreatitis is a known risk with GLP-1 class medicines. Severe, persistent stomach pain that radiates to the back, with or without vomiting, is a reason to seek urgent medical help rather than wait. The MHRA issued specific guidance on this risk for GLP-1 medicines in January 2026. Other situations that warrant immediate attention include signs of a serious allergic reaction, gallbladder symptoms or significant dehydration from prolonged vomiting or diarrhoea.

Tirzepatide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for anyone under 18. Women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because tirzepatide's effect on gastric emptying can reduce how much of the pill is absorbed. This is not a small-print detail, it is worth discussing with your prescriber before you begin.

A full account of the Mounjaro injection, including contraindications and interactions, is available through the eMC's SmPC, and our FAQs page covers the questions our prescribers hear most often from people starting out. If anything is unclear after reading, our team is available seven days a week.